PKD2 and autosomal recessive polycystic kidney disease: In fact, several studies demonstrated that V2 receptor antagonists (mozavaptan and/or tolvaptan) attenuate the progression of PKD in cpk mice and pcy mouse models of nephronophthisis (NPHP), ARPKD (PCK rats), and PKD2 (Pkd2WS25/− mice)14,47,48,55.